Whitehawk Therapeutics (WHWK) Consolidated Net Income (2010 - 2026)

Whitehawk Therapeutics (WHWK) has reported Consolidated Net Income for 17 consecutive years, with -$22.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income fell 130.4% year-over-year to -$22.2 million; the TTM figure through Mar 2026 stood at -$124.9 million (down 532.98% YoY), while the FY2025 annual figure was -$16.3 million, up 74.45% from the prior year.
• Consolidated Net Income rose to -$22.2 million in Q1 2026 per WHWK's latest filing, from -$29.3 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $73.0 million in Q1 2025 and bottomed at -$55.2 million in Q2 2025.
• Historically, Consolidated Net Income has averaged -$14.2 million across 5 years, with a median of -$16.3 million in 2023.
• Annual changes were most pronounced in 2022 — Consolidated Net Income slumped 1089.39% — and 2025, when it soared 471.15%.
• Whitehawk Therapeutics' Consolidated Net Income stood at -$13.9 million in 2022, then slipped by 16.93% to -$16.3 million in 2023, then climbed by 4.84% to -$15.5 million in 2024, then slumped by 89.28% to -$29.3 million in 2025, then rose by 24.26% to -$22.2 million in 2026.
• Business Quant data shows WHWK's Consolidated Net Income at -$22.2 million in Q1 2026, -$29.3 million in Q4 2025, and -$18.2 million in Q3 2025.